Mundipharma International Limited Release: Penthrox (Low Dose Methoxyflurane) Granted Marketing Authorization In France

Cambridge, UK, 21 June 2016 – Mundipharma International Limited today announced that Penthrox® (low dose methoxyflurane) has been granted marketing authorisation in France for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

Penthrox is manufactured by the Australian company Medical Developments International Limited who received the French marketing authorisation. Mundipharma has the exclusive product rights in 39 European markets including France, Belgium, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the United Kingdom.

“Mundipharma has a proud heritage in pain management and is committed to advancing important new therapeutics in this space,” commented Kate Hurtig, Head of Pain at Mundipharma International. “Penthrox is our first analgesic for use in the emergency care setting. It offers the potential to manage emergency pain in a completely different way to existing treatment options and we are excited about the prospect for growth which that brings.”

Currently in Europe, pain remains undertreated in both the pre-hospital1–3 and emergency department settings,4,5 where prevalence in the latter can be over 90%.5

Penthrox is a lightweight, self-administered, handheld inhaler that delivers 3ml methoxyflurane. Patients can titrate the amount of Penthrox they inhale, allowing them to control their own pain.6 Penthrox has been extensively used for over 30 years in Australia and New Zealand, therefore it has an established safety profile and efficacy data.7,8

-Ends-

About Mundipharma

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. The Mundipharma network has a presence in 51 countries with more than 7,800 employees across the world. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions.

Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide. For further information please visit: www.mundipharma.com

About Medical Developments International Ltd (ASX: MVP)

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

Back to news